Comparative Efficacy HCP brochure: empathy and education
This piece straddles a line: it’s 100% HCP, but the ultimate audience is a group of schizophrenia patients similar to those in the study who might benefit from a Long-Acting Injectable medication. So the challenge over many months of development for our team was to keep everything simple for patients while making accurate, justified statements HCPs could feel comfortable explaining.
Where’s that boxed warning and indication then? Oh yeah, always visible at the bottom of an asymmetric fold.
This piece was a solid step towards normalizing LAIs as a first-choice schizophrenia therapy.
And the back is all ISI, which is good and vital and unnecessary for this portfolio.